17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 118 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04184063
(ClinicalTrials.gov)
September 16, 201929/7/2019Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA)Progressive Supranuclear Palsy;Multiple System AtrophyDrug: NBMI;Other: PlaceboEmeraMedNULLCompleted40 Years85 YearsAll20Phase 2Slovenia
2EUCTR2018-000506-34-SI
(EUCTR)
04/02/201909/03/2018EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: NBMI
Product Code: NBMI
INN or Proposed INN: emeramide
Other descriptive name: N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE
NBMI Science Ltd.NULLNot RecruitingFemale: yes
Male: yes
20Phase 2Slovenia